BeOne Medicines Ltd. (NASDAQ:ONC) is likely one of the high high growth international stocks to buy right now. On September 9, Residents JMP analyst Reni Benjamin reiterated a Purchase ranking on BeOne Medicines Ltd. (NASDAQ:ONC) and set a value goal of $348.00.
On August 29, BeOne Medicines Ltd. (NASDAQ:ONC) introduced optimistic topline outcomes for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL), stating that the research met its main endpoint of total response charge (ORR) and exhibited clinically significant responses in uncommon B-cell lymphoma with appreciable unmet want.
Administration added that BeOne Medicines Ltd. (NASDAQ:ONC) would submit the information to world regulatory authorities for his or her evaluation and potential approval.
Domiciled in Switzerland, BeOne Medicines Ltd. (NASDAQ:ONC) is a worldwide oncology firm that discovers and develops reasonably priced, accessible, and revolutionary therapies for most cancers sufferers.
Whereas we acknowledge the potential of ONC as an funding, we consider sure AI shares provide larger upside potential and carry much less draw back threat. For those who’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
